No Data
No Data
Giant Biogene Places 33.2 Million Shares for About HK$1.63
Giant Biogene Holding (HKG:2367) successfully placed 33.2 million shares for about HK$1.63 billion to six placees, according to a Friday filing on the Hong Kong bourse. The average price for the Subsc
[Broker Focus] CMB International: China's pharmaceutical industry is expected to return to healthy growth and continues to be optimistic about leading innovative drugs and devices and high-growth medical consumer stocks
Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has declined by 21.4%, significantly outperforming the MSCI China Index by 32.5%. The MSCI China Healthcare Index has only rebounded 9% since its low on April 19; currently, the dynamic price-earnings ratio of the industry index is 26.3 times, which is still below the 12-year historical average. It is expected that the medical equipment trade-in policy will soon be implemented. The policy is strong, wide-ranging, and has a long duration, which will effectively stimulate demand for medical devices. The bank looks forward to the introduction of a national policy to support innovative drugs and innovative devices. The bank expects that as industry-supporting policies fall one after another
Giant Biogene Secures Funds for Expansion
Giant Biotech (02367) completed placement of 33.22 million shares
According to the Zhitong Finance App, Juzi Biotech (02367) announced that the seller's placement was completed on May 21, 2024, while the subscription was completed on May 24, 2024. A total of 33.22 million shares held by the seller have been successfully placed at a placement price of HK$49.40 per share to no less than six professional, institutional and/or individual investors. As far as the seller's placement is concerned, since all the conditions for the subscription have been fulfilled, a total of 33.22 million subscription shares have been issued to supplement the seller at a subscription price of HK$49.40 per share. The estimated net subscription price is approximately HK$48.97 per subscribed share.
Hong Kong Stock Concept Tracking | Beijing Pharmaceutical Documents Released! Regarding synthetic biology, brain-computer interface, etc., these companies have already laid out positions (with concept stocks)
The Zhitong Finance App learned that after the market on May 23, the General Office of the Beijing Municipal People's Government issued the “Beijing Action Plan to Accelerate Collaborative Innovation in Medicine and Health (2024-2026)” (Action Plan for short). The “Action Plan” is clear. By 2026, the total scale of the medical and health industry will reach 1.25 trillion yuan (of which the pharmaceutical industry's operating income will reach 240 billion yuan), and the fixed asset investment will be more than 10 billion yuan per year. It is worth noting that the action plan mentioned many new quality productivity examples such as synthetic organisms, genetic technology, and brain-computer interfaces. Meanwhile, at the Beijing Municipal Government Executive Meeting in March, research
Changes in Hong Kong stocks | Giant Biotech (02367) rose nearly 4%, explosives, continued the company's cash reserves were sufficient
Giant Biotech (02367) rose nearly 4%. As of press release, it was up 3.73% to HK$51.4, with a turnover of HK$229 million.
No Data